957 related articles for article (PubMed ID: 17306374)
1. Mechanisms of action of glucagon-like peptide 1 in the pancreas.
Doyle ME; Egan JM
Pharmacol Ther; 2007 Mar; 113(3):546-93. PubMed ID: 17306374
[TBL] [Abstract][Full Text] [Related]
2. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
3. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
Guo XH
Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice.
Lamont BJ; Li Y; Kwan E; Brown TJ; Gaisano H; Drucker DJ
J Clin Invest; 2012 Jan; 122(1):388-402. PubMed ID: 22182839
[TBL] [Abstract][Full Text] [Related]
5. Evidence for paracrine/autocrine regulation of GLP-1-producing cells.
Kappe C; Zhang Q; Holst JJ; Nyström T; Sjöholm A
Am J Physiol Cell Physiol; 2013 Nov; 305(10):C1041-9. PubMed ID: 23986202
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
Nielsen LL; Young AA; Parkes DG
Regul Pept; 2004 Feb; 117(2):77-88. PubMed ID: 14700743
[TBL] [Abstract][Full Text] [Related]
7. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.
Lee YS; Jun HS
Metabolism; 2014 Jan; 63(1):9-19. PubMed ID: 24140094
[TBL] [Abstract][Full Text] [Related]
8. Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents.
Arakawa M; Ebato C; Mita T; Hirose T; Kawamori R; Fujitani Y; Watada H
Biochem Biophys Res Commun; 2009 Dec; 390(3):809-14. PubMed ID: 19836346
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 and islet lipolysis.
Sörhede Winzell M; Ahrén B
Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.
Holz GG; Chepurny OG
Curr Med Chem; 2003 Nov; 10(22):2471-83. PubMed ID: 14529486
[TBL] [Abstract][Full Text] [Related]
11. Glucagon Potentiates Insulin Secretion Via β-Cell GCGR at Physiological Concentrations of Glucose.
Zhang Y; Han C; Zhu W; Yang G; Peng X; Mehta S; Zhang J; Chen L; Liu Y
Cells; 2021 Sep; 10(9):. PubMed ID: 34572144
[TBL] [Abstract][Full Text] [Related]
12. Incretins: their physiology and application in the treatment of diabetes mellitus.
Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
[TBL] [Abstract][Full Text] [Related]
13. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
[TBL] [Abstract][Full Text] [Related]
14. Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity.
Cabou C; Campistron G; Marsollier N; Leloup C; Cruciani-Guglielmacci C; Pénicaud L; Drucker DJ; Magnan C; Burcelin R
Diabetes; 2008 Oct; 57(10):2577-87. PubMed ID: 18633100
[TBL] [Abstract][Full Text] [Related]
15. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
Lam NT; Kieffer TJ
Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
[TBL] [Abstract][Full Text] [Related]
16. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
[TBL] [Abstract][Full Text] [Related]
17. Progesterone receptor membrane component 1 is a functional part of the glucagon-like peptide-1 (GLP-1) receptor complex in pancreatic β cells.
Zhang M; Robitaille M; Showalter AD; Huang X; Liu Y; Bhattacharjee A; Willard FS; Han J; Froese S; Wei L; Gaisano HY; Angers S; Sloop KW; Dai FF; Wheeler MB
Mol Cell Proteomics; 2014 Nov; 13(11):3049-62. PubMed ID: 25044020
[TBL] [Abstract][Full Text] [Related]
18. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
Göke R; Fehmann HC; Linn T; Schmidt H; Krause M; Eng J; Göke B
J Biol Chem; 1993 Sep; 268(26):19650-5. PubMed ID: 8396143
[TBL] [Abstract][Full Text] [Related]
19. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
van Genugten RE; van Raalte DH; Diamant M
Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
[TBL] [Abstract][Full Text] [Related]
20. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice.
Rieg T; Gerasimova M; Murray F; Masuda T; Tang T; Rose M; Drucker DJ; Vallon V
Am J Physiol Renal Physiol; 2012 Oct; 303(7):F963-71. PubMed ID: 22832924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
